BL1391: an established cell line from a human malignant peripheral nerve sheath tumor with unique genomic features.
Adaptor Proteins, Signal Transducing
/ genetics
Aged, 80 and over
Cell Cycle Proteins
/ genetics
Cell Line, Tumor
Cyclin D1
/ genetics
Cyclin-Dependent Kinase 4
/ genetics
Female
Gene Amplification
/ genetics
Gene Expression Profiling
Humans
Membrane Proteins
/ genetics
Nerve Sheath Neoplasms
/ genetics
Peripheral Nervous System Neoplasms
/ genetics
Proto-Oncogene Proteins
/ genetics
Transcription Factors
/ genetics
YAP-Signaling Proteins
Amplification
BL1391
Fusion transcript
MPNST
Neocentromere
Journal
Human cell
ISSN: 1749-0774
Titre abrégé: Hum Cell
Pays: Japan
ID NLM: 8912329
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
01
07
2020
accepted:
17
08
2020
pubmed:
29
8
2020
medline:
2
7
2021
entrez:
29
8
2020
Statut:
ppublish
Résumé
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive tumors, accounting for around 5% of all soft tissue sarcomas. A better understanding of the pathogenesis of these tumors and the development of effective treatments are needed. In this context, established tumor cell lines can be very informative, as they may be used for in-depth molecular analyses and improvement of treatment strategies. Here, we present the genomic and transcriptomic profiling analysis of a MPNST cell line (BL1391) that was spontaneously established in our laboratory from a primary tumor that had not been exposed to genotoxic treatment. This cell line shows peculiar genetic features, such as a large marker chromosome composed of high-copy number amplifications of regions from chromosomes 1 and 11 with an embedded neocentromere. Moreover, the transcriptome profiling revealed the presence of several fusion transcripts involving the CACHD1, TNMA4, MDM4, and YAP1 genes, all of which map to the amplified regions of the marker. BL1391 could be a useful tool to study genomic amplifications and neocentromere seeding in MPNSTs and to develop new therapeutic strategies.
Identifiants
pubmed: 32856169
doi: 10.1007/s13577-020-00418-7
pii: 10.1007/s13577-020-00418-7
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
CACHD1 protein, human
0
Cell Cycle Proteins
0
MDM4 protein, human
0
Membrane Proteins
0
Proto-Oncogene Proteins
0
Transcription Factors
0
YAP-Signaling Proteins
0
YAP1 protein, human
0
Cyclin D1
136601-57-5
CDK4 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
238-245Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 15413
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 20441
Organisme : Telemielolab
ID : INNOLABS - POR Puglia FESR-FSE 2014-2020
Organisme : Swedish Cancer Society
ID : CAN2017/269
Références
Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC; 2013.
Thway K, Fisher C. Malignant peripheral nerve sheath tumor: pathology and genetics. Ann Diagn Pathol. 2014;18(2):109–16.
pubmed: 24418643
doi: 10.1016/j.anndiagpath.2013.10.007
James AW, Shurell E, Singh A, Dry SM, Eilber FC. Malignant peripheral nerve sheath tumor. Surg Oncol Clin N Am. 2016;25(4):789–802.
pubmed: 27591499
doi: 10.1016/j.soc.2016.05.009
Hattori E, Oyama R, Kondo T. Systematic review of the current status of human sarcoma cell lines. Cells. 2019;8(2):157.
pmcid: 6406745
doi: 10.3390/cells8020157
Mandahl N, Heim S, Arheden K, Rydholm A, Willen H, Mitelman F. Three major cytogenetic subgroups can be identified among chromosomally abnormal solitary lipomas. Hum Genet. 1988;79(3):203–8.
pubmed: 3402992
doi: 10.1007/BF00366238
McGowan-Jordan J, Simons A, Schimd M. ISCN 2016: An international system for human cytogenomic signature. Basel: Karger; 2016.
doi: 10.1159/isbn.978-3-318-06861-0
Tolomeo D, L’Abbate A, Lonoce A, D’Addabbo P, Miccoli MF, Lo Cunsolo C, et al. Concurrent chromothripsis events in a case of TP53 depleted acute myeloid leukemia with myelodysplasia-related changes. Cancer Genet. 2019;237:63–8.
pubmed: 31447067
doi: 10.1016/j.cancergen.2019.06.009
Macchia G, Severgnini M, Purgato S, Tolomeo D, Casciaro H, Cifola I, et al. The hidden genomic and transcriptomic plasticity of giant marker chromosomes in cancer. Genetics. 2018;208(3):951–61.
pubmed: 29279323
doi: 10.1534/genetics.117.300552
Macchia G, Nord KH, Zoli M, Purgato S, D’Addabbo P, Whelan CW, et al. Ring chromosomes, breakpoint clusters, and neocentromeres in sarcomas. Genes Chromosom Cancer. 2015;54(3):156–67.
pubmed: 25421174
doi: 10.1002/gcc.22228
Nord KH, Macchia G, Tayebwa J, Nilsson J, Von Steyern FV, Brosjö O, et al. Integrative genome and transcriptome analyses reveal two distinct types of ring chromosome in soft tissue sarcomas. Hum Mol Genet. 2014;23(4):878–88.
pubmed: 24070870
doi: 10.1093/hmg/ddt479
Walther C, Mayrhofer M, Nilsson J, Hofvander J, Jonson T, Mandahl N, et al. Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis. Genes Chromosom Cancer. 2016;55(1):3–15.
pubmed: 26482321
doi: 10.1002/gcc.22285
Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv Prepr arXiv [Internet]. 2013; https://arxiv.org/abs/1303.3997
Thomer AK, Twidale MB, Guo J, Yoder MJ. Picard Tools. Conf Hum Factors Comput Syst - Proc. 2016.
Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28(18):i333–i339.
pubmed: 3436805
pmcid: 3436805
doi: 10.1093/bioinformatics/bts378
Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14(2):178–92.
pubmed: 22517427
doi: 10.1093/bib/bbs017
Arbajian E, Puls F, Antonescu CR, Amary F, Sciot R, Debiec-Rychter M, et al. In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets. Clin Cancer Res. 2017;23(23):7462–34.
doi: 10.1158/1078-0432.CCR-17-1856
Nicorici D, Satalan M, Edgren H, Kangaspeska S, Murumagi A, Kallioniemi O, et al. FusionCatcher—a tool for finding somatic fusion genes in paired-end RNA-sequencing data. bioRxiv [Internet]. 2014; https://biorxiv.org/content/biorxiv/early/2014/11/19/011650.full.pdf
Oyama R, Kito F, Takahashi M, Hattori E, Noguchi R, Takai Y, et al. Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors. Cancer Cell Int. 2020;20:58.
pubmed: 32099531
pmcid: 7031935
doi: 10.1186/s12935-020-1128-z
Aoki M, Nabeshima K, Nishio J, Ishiguro M, Fujita C, Koga K, et al. Establishment of three malignant peripheral nerve sheath tumor cell lines, FU-SFT8611, 8710 and 9817: conventional and molecular cytogenetic characterization. Int J Oncol. 2006;29(6):1421–8.
pubmed: 17088980
Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep. 2017;7(1):144992.
doi: 10.1038/s41598-017-15183-1
VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res. 2015;21(13):2905–10.
pubmed: 25941111
doi: 10.1158/1078-0432.CCR-14-0816
Fernández-Hernández R, Rafel M, Fusté NP, Aguayo RS, Casanova JM, Egea J, et al. Cyclin D1 localizes in the cytoplasm of keratinocytes during skin differentiation and regulates cell-matrix adhesion. Cell Cycle. 2013;12(15):2510–7.
pubmed: 23839032
pmcid: 3841329
doi: 10.4161/cc.25590
Bodempudi V, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, Piedra M, et al. Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol. 2009;29(14):3964–74.
pubmed: 19414599
pmcid: 2704746
doi: 10.1128/MCB.01153-08
Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res. 2011;17(7):1924–34.
pubmed: 21325289
doi: 10.1158/1078-0432.CCR-10-1551
Berner J, Sørlie T, Mertens F, Henriksen J, Sæter G, Mandahl N, et al. Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway. Genes, Chromosom Cancer. 1999;26(2):151–60.
doi: 10.1002/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.0.CO;2-A
Hu X, Wang Q, Tang M, Barthel F, Amin S, Yoshihara K, et al. TumorFusions: an integrative resource for cancer-associated transcript fusions. Nucleic Acids Res. 2018;46(D1):D1144–1149.
pubmed: 29099951
doi: 10.1093/nar/gkx1018
Fullenkamp CA, Hall SL, Jaber OI, Pakalniskis BL, Savage EC, Savage JM, et al. TAZ and YAP are frequently activated oncoproteins in sarcomas. Oncotarget. 2016;7(21):30094–10808.
pubmed: 27129148
pmcid: 5058666
doi: 10.18632/oncotarget.8979
Xiong S, Pant V, Zhang Y, Aryal NK, You MJ, Kusewitt D, et al. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. J Pathol. 2017;241(4):501–10.
pubmed: 27925213
pmcid: 5315583
doi: 10.1002/path.4854
Stephens GJ, Cottrell GS. CACHD1: a new activity-modifying protein for voltage-gated calcium channels. Channels (Austin). 2019;3(1):120–3.
doi: 10.1080/19336950.2019.1600968
Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962–71.
pubmed: 18579750
pmcid: 2492741
doi: 10.1101/gad.1664408
Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosom Cancer. 2013;52(8):775–84.
pubmed: 23737213
doi: 10.1002/gcc.22073
Kao YC, Lee JC, Zhang L, Sung YS, Swanson D, Hsieh TH, et al. Recurrent YAP1 and KMT2A gene rearrangements in a subset of MUC4-negative sclerosing epithelioid fibrosarcoma. Am J Surg Pathol. 2019;44(3):368–77.
doi: 10.1097/PAS.0000000000001382
Puls F, Aigamy A, Flucke U, Menzel T, Sumathi VP, Ploegmakers M, Stoehr R, Kindblom L-G, Hansson M, Sydow S, Arbajian EMF. Recurrent fusions between YAP1 and KMT2A in morphologically distinct neoplasms within the spectrum of low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma. Am J Surg Pathol. 2020;44(5):594–606.
pubmed: 31913156
doi: 10.1097/PAS.0000000000001423
Tucker RP, Chiquet-Ehrismann R. Teneurins: a conserved family of transmembrane proteins involved in intercellular signaling during development. Dev Biol. 2006;290(2):237–45.
pubmed: 16406038
doi: 10.1016/j.ydbio.2005.11.038
Rebolledo-Jaramillo B, Ziegler A. Teneurins: an integrative molecular, functional, and biomedical overview of their role in cancer. Front Neurosci. 2018;12:937.
pubmed: 30618566
pmcid: 6297388
doi: 10.3389/fnins.2018.00937
Haupt S, Mejia-Hernandez JO, Vijayakumaran R, Keam SP, Haupt Y. The long and the short of it: the MDM4 tail so far. J Mol Cell Biol. 2019;11(3):231–44.
pubmed: 30689920
pmcid: 6478121
doi: 10.1093/jmcb/mjz007
Rocchi M, Archidiacono N, Schempp W, Capozzi O, Stanyon R. Centromere repositioning in mammals. Heredity (Edinb). 2012;108(1):59–67.
doi: 10.1038/hdy.2011.101
Tolomeo D, Capozzi O, Stanyon RR, Archidiacono N, D’Addabbo P, Catacchio CR, et al. Epigenetic origin of evolutionary novel centromeres. Sci Rep. 2017;7:41980.
pubmed: 28155877
pmcid: 5290474
doi: 10.1038/srep41980
Marshall OJ, Chueh AC, Wong LH, Choo KHA. Neocentromeres: new insights into centromere structure, disease development, and karyotype evolution. Am J Hum Genet. 2008;82(2):261–82.
pubmed: 18252209
pmcid: 2427194
doi: 10.1016/j.ajhg.2007.11.009
Zeitlin SG, Baker NM, Chapados BR, Soutoglou E, Wang JYJ, Berns MW, et al. Double-strand DNA breaks recruit the centromeric histone CENP-A. Proc Natl Acad Sci USA. 2009;106(37):15762–7.
pubmed: 19717431
doi: 10.1073/pnas.0908233106
Garsed DW, Marshall OJ, Corbin VDA, Hsu A, DiStefano L, Schröder J, et al. The architecture and evolution of cancer neochromosomes. Cancer Cell. 2014;26(5):653–67.
pubmed: 25517748
doi: 10.1016/j.ccell.2014.09.010